Contributions
Abstract: EP1386
Type: ePoster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Objective: Despite several cognitive tests have been validated in Multiple Sclerosis (MS), a neuropsychological evaluation is not routinely implemented in the Expanded Disability Status Scale (EDSS) scoring.
Methods: Our aim was to include the Brief International Cognitive Assessment for MS (BICAMS) and orientation tests (OTs) as a quick and objective method to measure the Cognitive Functional System (CFS), and to evaluate its impact on the EDSS on a large cohort of MS patients. We compared EDSS calculated as usual (Native-EDSS) and after the use of the BICAMS and orientation test (NPS-EDSS).
Results: We tested 604 MS patients (399 women, age 42.5±11.3 years, education 12.7±3.7 years) with BICAMS, OTs, and EDSS. 384 patients (63.6%) had at least one altered test at the BICAMS. Older age (OR 1.037; CI 1.021, 1.053; p=0.001), higher education (OR 0.914; CI 0.873, 0.957; p=0.001), higher native-EDSS (OR 1.331; CI 1.208, 1.466; p=0.001), male gender (OR 1.462; CI 1.022, 2.092; p=0.038), longer disease duration (OR 1.042; CI 1.021, 1.063; p=0.001), and SP-MS disease course (OR 2.831; CI 1.593, 1.5.030; p=0.001), were individually associated with at least one impaired BICAMS test. Native-EDSS was different from the NPS-EDSS (-0.112; p< 0.001) in 99 patients (16%). When considering patients with a Native-EDSS ≤4.0 the proportion of miscalculated EDSS was 25%.
Conclusions: The use of brief neuropsychological tests leads to a more accurate CFS calculation in two-thirds of MS patients, and a more accurate EDSS calculation in 25% of patients with an EDSS score ≤4.0. This may help clinicians to better recognize cognitive impairment in everyday clinical practice, especially in the case of isolated cognitive worsening.
Disclosure:
Francesco Saccà received personal compensation from Novartis, Almirall, Genzyme, Forward Pharma, and TEVA for public speaking, editorial work and advisory boards;
Teresa Costabile has nothing to disclose;
Antonio Carotenuto has nothing to disclose;
Roberta Lanzillo received personal compensation from Novartis, Almirall, Genzyme, Merk Serono, Biogen, and TEVA for public speaking, editorial work and advisory boards;
Marcello Moccia received compensation for public speaking from Genzyme;
Chiara Pane has nothing to disclose;
Cinzia Valeria Russo has nothing to disclose;
Anna Maria Barbarulo has nothing to disclose;
Sara Casertano has nothing to disclose;
Fabiana Rossi has nothing to disclose;
Elisabetta Signoriello has nothing to disclose;
Giacomo Lus received compensation for public speaking, and advisory boards from Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA.;
Vincenzo Bresciamorra received compensation for public speaking, and advisory boards from Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA.
Abstract: EP1386
Type: ePoster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Objective: Despite several cognitive tests have been validated in Multiple Sclerosis (MS), a neuropsychological evaluation is not routinely implemented in the Expanded Disability Status Scale (EDSS) scoring.
Methods: Our aim was to include the Brief International Cognitive Assessment for MS (BICAMS) and orientation tests (OTs) as a quick and objective method to measure the Cognitive Functional System (CFS), and to evaluate its impact on the EDSS on a large cohort of MS patients. We compared EDSS calculated as usual (Native-EDSS) and after the use of the BICAMS and orientation test (NPS-EDSS).
Results: We tested 604 MS patients (399 women, age 42.5±11.3 years, education 12.7±3.7 years) with BICAMS, OTs, and EDSS. 384 patients (63.6%) had at least one altered test at the BICAMS. Older age (OR 1.037; CI 1.021, 1.053; p=0.001), higher education (OR 0.914; CI 0.873, 0.957; p=0.001), higher native-EDSS (OR 1.331; CI 1.208, 1.466; p=0.001), male gender (OR 1.462; CI 1.022, 2.092; p=0.038), longer disease duration (OR 1.042; CI 1.021, 1.063; p=0.001), and SP-MS disease course (OR 2.831; CI 1.593, 1.5.030; p=0.001), were individually associated with at least one impaired BICAMS test. Native-EDSS was different from the NPS-EDSS (-0.112; p< 0.001) in 99 patients (16%). When considering patients with a Native-EDSS ≤4.0 the proportion of miscalculated EDSS was 25%.
Conclusions: The use of brief neuropsychological tests leads to a more accurate CFS calculation in two-thirds of MS patients, and a more accurate EDSS calculation in 25% of patients with an EDSS score ≤4.0. This may help clinicians to better recognize cognitive impairment in everyday clinical practice, especially in the case of isolated cognitive worsening.
Disclosure:
Francesco Saccà received personal compensation from Novartis, Almirall, Genzyme, Forward Pharma, and TEVA for public speaking, editorial work and advisory boards;
Teresa Costabile has nothing to disclose;
Antonio Carotenuto has nothing to disclose;
Roberta Lanzillo received personal compensation from Novartis, Almirall, Genzyme, Merk Serono, Biogen, and TEVA for public speaking, editorial work and advisory boards;
Marcello Moccia received compensation for public speaking from Genzyme;
Chiara Pane has nothing to disclose;
Cinzia Valeria Russo has nothing to disclose;
Anna Maria Barbarulo has nothing to disclose;
Sara Casertano has nothing to disclose;
Fabiana Rossi has nothing to disclose;
Elisabetta Signoriello has nothing to disclose;
Giacomo Lus received compensation for public speaking, and advisory boards from Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA.;
Vincenzo Bresciamorra received compensation for public speaking, and advisory boards from Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA.